Refractory Thyrotoxicosis: Report of Two Cases and Literature Review
Asian Journal of Case Reports in Surgery,
Page 1-4
Abstract
Thyrotoxicosis occurs in approximately 2% of women and 0.2% of men (1) Patients with thyrotoxicosis usually present with heat intolerance, palpitations, anxiety, fatigue, weight loss, muscle weakness, diarrhea, and in women – irregular menses. Clinical findings may include tremor, tachycardia, lid lag, and goiter. Causes of thyrotoxicosis are Grave’s disease, toxic multinodular goiter, thyroiditis and exogenous ingestion of thyroid hormone. In overt thyrotoxicosis, the serum value of TSH is decreased and free thyroxine (T4) or free tri-iodothyronine (T3), or both, are raised. Conventional management of thyrotoxicosis includes antithyroid drugs. (2) Very rarely, patients may be resistant to these modalities and require additional management. Refractory thyrotoxicosis is when patients do not respond to conventional treatments.
Keywords:
- Thyrotoxicosis
- refractory thyrotoxicosis
- thyroidectomy
How to Cite
References
DOI:10.1136/bmj.332.7554.1369
Cooper DS. Hyperthyroidism. The Lancet, 2003;362(9382):459–468.
DOI:10.1016/s0140-6736(03)14073-1
Calissendorff J, Falhammar H. Lugol's solution and other iodide preparations: perspectives and research directions in Graves' disease. Endocrine. 2017;58(3): 467-473.
DOI:10.1007/s12020-017-1461-8
Jude EB, Dale J, Kumar S, Dodson PM. Treatment of thyrotoxicosis resistant to carbimazole with corticosteroids,” Postgraduate Medical Journal. 1996;72( 850):489–491.
Tsang W, Houlden RL. Amiodarone-induced thyrotoxicosis: a review. Can J Cardiol. 2009;25(7):421-424.
DOI:10.1016/s0828-282x(09)70512-4
Corvilain B, Schinohoritis P. Carbimazole—Resistant thyrotoxicosis, Postgraduate Medical Journal. 1997; 73(864):686.
Winsa B, Rastad J, Larsson E et al. Total thyroidectomy in therapy-resistant Graves' disease, Surgery. 1994;116(6): 1068–1075.
Holm LE, Lundell G, Dahlqvist I, Israelsson A. Cure rate after 131I therapy for hyperthyroidism. Acta Radiol Oncol. 1981; 20:161-6
Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352:905– 917.
Northcutt RC, Stiel JN, Hollifield JW, Stant EG, Jr. 1969 The influence of cholestyramine on thyroxine absorption. JAMA. 208:1857–1861.
Sebastián-Ochoa A, Quesada-Charneco M, Fernández-García D, Reyes-García R, Rozas-Moreno P, Escobar-Jiménez F. Dramatic response to cholestyramine in a patient with Graves' disease resistant to conventional therapy, Thyroid. 2008; 18(10):1115–1117.
Bogazzi F, Bartalena L, Campomori A et al. Treatment with lithium prevents serum thyroid hormone increase after thionamide withdrawal and radioiodine therapy in patients with graves' disease, Journal of Clinical Endocrinology and Metabolism. 2002;87(10):4490– 4495.
Langley RW, Burch HB. Perioperative management of the thyrotoxic patient. Endocrinology and Metabolism Clinics of North America. 2003;32(2):519–534.
DOI: 10.1016/s0889-8529(03)00010-0
-
Abstract View: 106 times
PDF Download: 40 times
